FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3116359097> ?p ?o ?g. }

• W3116359097 endingPage "242" @default.
• W3116359097 startingPage "231" @default.
• W3116359097 abstract "Abstract 5‐azacytidine (5‐AZA) is considered the standard of care for patients with high‐risk myelodysplastic syndromes (MDS) and patients with acute myeloid leukemia (AML) not candidate for intensive chemotherapy. However, even after an initial favorable response, almost all patients relapse, with the exact mechanisms underlying primary or secondary 5‐AZA resistance remaining largely unknown. Several reports have previously demonstrated the significance of hypoxia in the regulation of both physiological and malignant hematopoiesis. In MDS, high hypoxia inducible factor 1α (Hif‐1α) expression has been correlated with poor overall survival and disease progression, while its involvement in the disease's pathogenesis was recently reported. We herein investigated the possible association of the Hif‐1α signaling pathway with response to 5‐AZA therapy in MDS/AML patients. Our data demonstrated that 5‐AZA‐responders present with higher Hif‐1α mRNA and protein expression compared to 5‐AZA‐non‐responders/stable disease patients, before the initiation of therapy, while, interestingly, no significant differences in Hif‐1α mRNA expression at the 6‐month follow‐up were observed. Moreover, we found that 5‐AZA‐responders exhibited elevated mRNA levels of the Hif‐1α downstream targets lactate dehydrogenase a (LDHa) and BCL2 interacting protein 3 like (BNIP3L), a further indication of an overactivated Hif‐1a signaling pathway in these patients. Kaplan–Meier survival analysis revealed a significant correlation between high Hif‐1α mRNA expression and better survival rates, while logistic regression analysis showed that Hif‐1α mRNA expression is an independent predictor of response to 5‐AZA therapy. From the clinical point of view, apart from proposing Hif‐1α mRNA expression as a significant predictive factor for response to 5‐AZA, our data offer new perspectives on MDS combinational therapies, suggesting a potential synergistic activity of 5‐AZA and Hif‐1α inducers, such as propyl hydroxylases inhibitors (PHDi)." @default.
• W3116359097 created "2021-01-05" @default.
• W3116359097 creator A5006283366 @default.
• W3116359097 creator A5013439164 @default.
• W3116359097 creator A5016064577 @default.
• W3116359097 creator A5017439064 @default.
• W3116359097 creator A5019954410 @default.
• W3116359097 creator A5022847672 @default.
• W3116359097 creator A5024960041 @default.
• W3116359097 creator A5025768647 @default.
• W3116359097 creator A5029656734 @default.
• W3116359097 creator A5032351167 @default.
• W3116359097 creator A5033425321 @default.
• W3116359097 creator A5036771098 @default.
• W3116359097 creator A5042804433 @default.
• W3116359097 creator A5048761931 @default.
• W3116359097 creator A5048932486 @default.
• W3116359097 creator A5060730234 @default.
• W3116359097 creator A5063213358 @default.
• W3116359097 creator A5065305973 @default.
• W3116359097 creator A5066644658 @default.
• W3116359097 creator A5068780868 @default.
• W3116359097 creator A5088890021 @default.
• W3116359097 date "2021-01-01" @default.
• W3116359097 modified "2023-10-16" @default.
• W3116359097 title "Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5‐azacytidine—data from the Hellenic myelodysplastic syndrome study group" @default.
• W3116359097 cites W1965827991 @default.
• W3116359097 cites W1981120003 @default.
• W3116359097 cites W1985458442 @default.
• W3116359097 cites W1985704394 @default.
• W3116359097 cites W1988907854 @default.
• W3116359097 cites W1989027751 @default.
• W3116359097 cites W2002466862 @default.
• W3116359097 cites W2010394923 @default.
• W3116359097 cites W2011420389 @default.
• W3116359097 cites W2015157460 @default.
• W3116359097 cites W2057199368 @default.
• W3116359097 cites W2062886892 @default.
• W3116359097 cites W2068141056 @default.
• W3116359097 cites W2080274549 @default.
• W3116359097 cites W2087377825 @default.
• W3116359097 cites W2104178560 @default.
• W3116359097 cites W2104457605 @default.
• W3116359097 cites W2118771330 @default.
• W3116359097 cites W2129510594 @default.
• W3116359097 cites W2129739112 @default.
• W3116359097 cites W2141035582 @default.
• W3116359097 cites W2148428508 @default.
• W3116359097 cites W2158535498 @default.
• W3116359097 cites W2177430595 @default.
• W3116359097 cites W2215824313 @default.
• W3116359097 cites W2265091238 @default.
• W3116359097 cites W2340628750 @default.
• W3116359097 cites W2521747815 @default.
• W3116359097 cites W2548477270 @default.
• W3116359097 cites W2594382910 @default.
• W3116359097 cites W2620456937 @default.
• W3116359097 cites W2772063923 @default.
• W3116359097 cites W2888716212 @default.
• W3116359097 doi "https://doi.org/10.1002/hon.2834" @default.
• W3116359097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33332639" @default.
• W3116359097 hasPublicationYear "2021" @default.
• W3116359097 type Work @default.
• W3116359097 sameAs 3116359097 @default.
• W3116359097 citedByCount "1" @default.
• W3116359097 countsByYear W31163590972022 @default.
• W3116359097 crossrefType "journal-article" @default.
• W3116359097 hasAuthorship W3116359097A5006283366 @default.
• W3116359097 hasAuthorship W3116359097A5013439164 @default.
• W3116359097 hasAuthorship W3116359097A5016064577 @default.
• W3116359097 hasAuthorship W3116359097A5017439064 @default.
• W3116359097 hasAuthorship W3116359097A5019954410 @default.
• W3116359097 hasAuthorship W3116359097A5022847672 @default.
• W3116359097 hasAuthorship W3116359097A5024960041 @default.
• W3116359097 hasAuthorship W3116359097A5025768647 @default.
• W3116359097 hasAuthorship W3116359097A5029656734 @default.
• W3116359097 hasAuthorship W3116359097A5032351167 @default.
• W3116359097 hasAuthorship W3116359097A5033425321 @default.
• W3116359097 hasAuthorship W3116359097A5036771098 @default.
• W3116359097 hasAuthorship W3116359097A5042804433 @default.
• W3116359097 hasAuthorship W3116359097A5048761931 @default.
• W3116359097 hasAuthorship W3116359097A5048932486 @default.
• W3116359097 hasAuthorship W3116359097A5060730234 @default.
• W3116359097 hasAuthorship W3116359097A5063213358 @default.
• W3116359097 hasAuthorship W3116359097A5065305973 @default.
• W3116359097 hasAuthorship W3116359097A5066644658 @default.
• W3116359097 hasAuthorship W3116359097A5068780868 @default.
• W3116359097 hasAuthorship W3116359097A5088890021 @default.
• W3116359097 hasConcept C104317684 @default.
• W3116359097 hasConcept C126322002 @default.
• W3116359097 hasConcept C127561419 @default.
• W3116359097 hasConcept C143998085 @default.
• W3116359097 hasConcept C178790620 @default.
• W3116359097 hasConcept C181199279 @default.
• W3116359097 hasConcept C185592680 @default.
• W3116359097 hasConcept C203014093 @default.
• W3116359097 hasConcept C2777318727 @default.
• W3116359097 hasConcept C2778461978 @default.

• next